Adaptive Biotechnologies Corp (NAS:ADPT)
$ 6.29 -0.15 (-2.33%) Market Cap: 950.41 Mil Enterprise Value: 791.33 Mil PE Ratio: 0 PB Ratio: 4.25 GF Score: 78/100

Adaptive Biotechnologies Corp at Goldman Sachs Global Healthcare Conference Transcript

Jun 15, 2022 / 05:00PM GMT
Release Date Price: $7.15 (+11.02%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good morning everyone, thanks for joining us. Really pleased to have the Adaptive team here with us. We have Chad Robins, CEO of the company; and Tycho Peterson, CFO of the company. With that, Chad, can I open it to you for opening comments here?

Chad M. Robins
Adaptive Biotechnologies Corporation - Co-Founder, CEO & Chairman

Sure. So we founded the company in 2009 with my brother, Harlan, [spun-off] Fred Hutchinson Cancer Research Center based on the premise that if we could learn to kind of read and translate how the adaptive immune system naturally both detects and treat disease that we could create clinical products both in diagnostics for earlier detection of disease, and we could harness the power of the immune system as a targeting molecule for therapeutics and drug discovery. And so that's what we've done.

We've -- the business is comprised of really 2 segments. One is in MRD or minimal residual disease. What's different about our MRD is specifically focused on

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot